🇺🇸

US SEC Filing Intelligence

· daily

US Material Events SEC 8-K Filings — October 07, 2026

Today's filings reveal a market actively reallocating capital through M&A, spin-offs, and refinancings. Notable transactions include First Digital's $250M SPAC merger, Healthcare Services Group's $93.5M acquisition of NEXDINE, and Ultragenyx's $210M PRV sale. Several companies are bolstering liquidity or reducing debt costs, including Magnite's third debt repricing and BKV's $1.2B power equipment contract. Leadership transitions are widespread, with new CFOs at FuelCell Energy, Ocean Power, and Tessera, and a major C-suite restructuring at lululemon. Financial performance is mixed: Richardson Electronics shows strong growth (sales +18.9% YoY, net income +112.6%), while Greenlane's subsidiaries are in liquidation. The SPAC sector is active with new IPOs and business combinations, but some deals face tight deadlines and execution risks.

50 high priority 50 total filings
· daily

Insider Trading Pulse — October 07, 2026

The October 7, 2026 insider trading digest is dominated by two distinct narratives. First, Vail Resorts (MTN) accounts for the overwhelming majority of filings, with a broad-based equity award cycle across executives and directors. Second, IRIDEX Corp (IRIX) shows a 10% owner aggressively accumulating shares in a series of open-market purchases. No open-market sales were detected in the enriched data, and no pledges were reported. The insider activity skews heavily toward bullish signals, particularly in IRIDEX where a significant owner is buying at depressed levels, while Vail's awards are routine compensation events. Key themes: (1) insider accumulation in IRIDEX signals conviction; (2) Vail's equity awards signal confidence in long-term value; (3) no insider selling detected across any filing — a notable bullish signal for the day.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — October 07, 2026

The sole filing in this digest is from Procter & Gamble (PG), a Dow 30 constituent, regarding a shareholder proposal (Item 5) on eligibility thresholds. The filing is a supplemental proxy statement issued ahead of the October 13, 2026 Annual Meeting. The Board reaffirms its recommendation to vote AGAINST the proposal, citing the SEC's pending rulemaking on Rule 14a-8. The sentiment is neutral, and materiality is low (3/10) as it is a procedural governance matter with no direct financial impact. No period-over-period comparisons, insider trading, capital allocation, or forward-looking financial data were provided in this filing, limiting quantitative insights. The key takeaway is that PG is taking a cautious, wait-and-see approach to potential regulatory changes in shareholder proposal rules, which may signal a broader corporate governance trend among large-cap companies. However, the filing does not contain actionable investment signals, risks, or opportunities for investors. Given the limited enriched data, this digest focuses on the governance implications and the upcoming AGM catalyst.

1 medium 1 total filings
· daily

Global High-Priority Regulatory Events — October 07, 2026

This digest covers 41 filings, dominated by severe distress signals across multiple sectors. The most critical theme is a wave of insolvencies and delistings, with 8 companies in active CIRP (Corporate Insolvency Resolution Process) and 4 receiving final delisting notices from Nasdaq, including NUSATRIP, Sangamo Therapeutics, and Aditxt. A significant regulatory enforcement action was taken by SEBI against Rashi Equisearch. On the M&A front, activity is mixed: a major SPAC merger values First Digital at $250M, while Adani Energy Solutions pursues strategic infrastructure growth. Period-over-period data reveals stark contrasts; Richardson Electronics posted a 112.6% surge in net income, while Greenlane Holdings' subsidiaries were liquidated, and Abans Financial's subsidiary saw a 41% revenue decline. The overall sentiment is heavily bearish, with a high concentration of default and insolvency events creating a 'watch list' of companies facing existential threats. The most actionable intelligence lies in the contrast between fundamentally strong companies facing temporary regulatory hurdles (like Polycab India) and those with terminal business models (like Greenlane). The SPAC market shows signs of life but with significant execution risk, as seen in the tight deadlines for Charlton Aria Acquisition Corp and Launch Two Acquisition Corp.

41 high priority 41 total filings
· daily

US SEC Filings Daily Market Digest — October 07, 2026

The October 7, 2026 filing batch reveals a market bifurcated between high-growth consumer lending and distressed micro-caps. SPAC activity dominates with three major business combinations targeting critical minerals (Nth Cycle), stablecoins (First Digital), and national security tech (REDLattice), collectively valued at over $835M. Period-over-period comparisons show stark contrasts: Figure Technology's consumer loan volume surged 107% YoY while Odyssey Marine's revenue collapsed 51% and NUSATRIP faces delisting. Insider ownership filings highlight Fidelity's 10.7% Illumina stake and Coastlands' 6.67% OnKure position. Forward-looking guidance from Rezolve AI ($360M revenue target) and Robo.AI ($600M FY2026) signal growth ambitions but are tempered by cash burn warnings. The delisting of NUSATRIP and voluntary withdrawal of Viking Acquisition underscore ongoing market discipline for non-performing entities.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — October 07, 2026

The 9 filings in the S&P 500 Consumer Discretionary stream for October 7, 2026, reveal a sector dominated by insider activity, primarily at MGM Resorts International, where six executives engaged in routine, neutral tax-withholding transactions following the vesting of restricted stock units. This pattern, while not signaling concern, highlights significant equity compensation and insider alignment. In contrast, two notable open-market sales under Rule 10b5-1 plans by the CEOs of Yum Brands and eBay, and a sale by Starbucks' international CEO, introduce a bearish undertone, suggesting pre-planned profit-taking or potential caution at these consumer-facing giants. The lack of any forward-looking guidance, period-over-period financial comparisons, or capital allocation changes in these filings creates a data vacuum, making it impossible to assess sector-wide growth or margin trends. The primary actionable intelligence is the divergence between routine insider activity at MGM and the more deliberate sales at Yum, Starbucks, and eBay, which warrant monitoring for any subsequent negative catalysts. The overall sector sentiment is mixed, with a neutral baseline from MGM's filings overshadowed by the negative signals from the three consumer brand companies.

9 high priority 9 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — October 07, 2026

The three S&P 500 Healthcare filings this week reveal a sector actively restructuring for growth and capital efficiency, while insider activity remains muted. Boston Scientific is undertaking a major operational realignment into three new segments (Interventional Therapies, Rhythm Solutions, MedSurg) effective January 2027, signaling a strategic pivot to accelerate decision-making and integrate its pending Penumbra acquisition. Medtronic has filed a 425 communication for a high-stakes exchange offer to spin off MiniMed Group, a 9/10 materiality event that will reshape its diabetes care exposure. In contrast, Moderna's CFO transaction was a routine tax withholding, offering no directional signal. No period-over-period financial trends or guidance changes were present in these filings, but the structural moves at BSX and MDT represent significant portfolio catalysts. The key actionable insight is the divergence between BSX's bullish internal reorganization and MDT's complex separation, both requiring close monitoring of execution risks.

3 high priority 3 total filings
· daily

US Earnings Financial Results SEC Filings — October 07, 2026

The 15 filings in this stream (excl. 4 non-material Pillarstone REIT filings and 2 shell companies) present a highly polarized earnings landscape. Dominant themes are a sharp bifurcation between mature, cash-generating market leaders (Costco, Cintas, Constellation Brands) delivering steady growth and shareholder returns, and a cluster of pre-revenue or distressed entities (Mag Magna, Applied Digital, Resources Connection, Protopia, Starguide) where cash burn, widening losses, and liquidity concerns are severe. Portfolio-level trends show that 5 of 7 revenue-generating companies (71%) reported positive YoY revenue growth (avg. +8.5%), but margin pressure is visible across the sample, with gross margin compression ranging from -3 basis points (Costco) to -190 bps (Resources Connection). A notable pattern is the prevalence of significant non-cash charges: a $1.05B impairment at Concentrix, a $76.4M gain absence at Neogen, and a $129K write-off at Protopia, distorting underlying operating trends. Insider trading activity was sparse but notable—Cintas and Levi's showed no insider sales during strong buyback quarters, a mild bullish signal. Capital allocation is bifurcated: Costco and Cintas are aggressively returning capital via buybacks/dividends, while distressed companies are burning cash and diluting shareholders (Mag Magna +230% share count). The key actionable takeaway is to favor companies with pricing power and organic volume growth (Costco, Constellation Beer) and avoid entities with negative revenue, rapid cash burn, and toxic financing structures (Mag Magna, Applied Digital).

15 high priority 15 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 07, 2026

The seven proxy filings reveal a polarized landscape in executive compensation and governance. Flexible Solutions and CISO Global show contrasting pay-performance alignment: Flexible cut CEO pay 30% despite TSR improvement but net income collapsed 74%, while CISO awarded 311% pay increases to executives who subsequently resigned. M&A activity dominates high-materiality filings: Centerspace's fixed-exchange merger with IRT and Charlton Aria's SPAC combination with KQC Quantum both carry significant execution and valuation risks. Onconetix continues its struggle with Nasdaq compliance, seeking a third reverse split in two years amid heavy dilution from PIPE and equity line transactions. In contrast, Clorox and SLR Investment present routine governance updates with strong insider ownership and enhanced risk oversight, offering stability. Overall, the stream highlights a divergence between companies using equity to retain talent versus those facing shareholder dilution and leadership churn.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 07, 2026

The IPO pipeline is active with three S-1 filings on October 7, 2026, spanning industrial automation, medical devices, and pre-clinical biotech. FireFly Automatix seeks to go public despite a high-risk profile of net losses and significant debt, including multiple 11% and 15% debentures. Centinel Spine offers a mixed outlook with no near-term dividend policy and substantial dilution risks, but benefits from a 180-day lock-up period for insiders. Salarius Pharmaceuticals (Decoy Therapeutics) is a pre-clinical biotech with limited cash ($8.0M) and no revenue, but recently raised $3.85M through warrant exercises, signaling a focus on near-term survival over growth. Across filings, period-over-period data would highlight cash burn rates, but only Salarius provides forward-looking cash runway; all three companies lack product revenue, underscoring a speculative IPO environment. No insider trading activity was reported, limiting conviction signals. The pipeline is dominated by high-risk, pre-revenue companies, suggesting investor caution is warranted.

3 high priority 3 total filings
· daily

US Executive Officer Management Changes SEC — October 07, 2026

The October 7, 2026 executive and director change filings reveal a wave of leadership transitions across US-listed companies, with notable activity in the technology and industrial sectors. Key themes include a significant number of CFO changes (BiomX, FuelCell Energy, Nukkleus, Advasa, Alkami, Matternet) and board refreshments (Crane NXT, WillScot, BCB Bancorp, TE Connectivity, Nutanix). Several transitions are tied to major corporate actions, such as Corteva's spin-off of Vylor Inc. and Boston Scientific's segment reorganization, which signal strategic pivots. Compensation packages for new executives are substantial, indicating competitive talent markets, particularly in tech and healthcare. While most transitions are orderly, BiomX's going concern qualification and CEO compensation structure, along with Matternet's CFO departure and option extension, warrant close monitoring. Overall, the period reflects a healthy churn in leadership, with a mix of routine governance updates and strategic appointments that could impact company performance and investor sentiment.

17 high priority 17 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — October 07, 2026

This digest covers a single filing from Greenlane Holdings, Inc., which falls squarely within the Bankruptcy & Insolvency stream. The company’s 8-K reveals that four subsidiaries made assignments for the benefit of creditors (ABCs) under Florida law, effectively transferring substantially all assets to an assignee for liquidation. This action results in deconsolidation, removing $594,573 in assets and $3,754,180 in liabilities from the balance sheet, though liabilities are not discharged. Pro forma financials show a dramatic 95% revenue decline from $4.355M to $225,000 for FY2025, while net loss improves from $85.580M to $48.117M due to the removal of subsidiary losses. Critically, the parent company received no consideration for the assignments and continues to report significant operating losses and unrealized losses on digital assets, indicating a deeply distressed financial position. The negative sentiment and high materiality (9/10) underscore a severe solvency crisis with no apparent turnaround path, making this a high-risk event for stakeholders.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 07, 2026

The October 7, 2026, board room change filings reveal a significant wave of corporate restructuring and leadership transitions across the US market, with a notable concentration in the industrial and technology sectors. The most critical development is Corteva's successful spin-off of its seed business into Vylor Inc., a major strategic move that triggered a complete board and C-suite overhaul, representing the highest materiality event in this batch. A clear pattern of orderly CFO transitions is evident, with FuelCell Energy, Alkami Technology, and Advasa Holdings all announcing CFO changes with structured transition periods, suggesting proactive succession planning rather than crisis-driven departures. The data also shows a trend of appointing directors with deep operational and regulatory expertise, such as Dr. Jeong H. Kim at Crane NXT (former Bell Labs President) and Donald Slager at WillScot (former Republic Services CEO), signaling a focus on governance strengthening. While no period-over-period financial comparisons were available in these specific filings, the forward-looking data on executive compensation packages (e.g., Hims & Hers' $3M RSU grant to new CAO) and separation agreements (e.g., Matternet's $156K CFO severance) provide actionable intelligence on company financial health and talent retention strategies. The mixed sentiment at BiomX/Tessera, with its going concern qualification and performance-based CEO equity awards, represents the highest-risk situation requiring immediate investor attention.

17 high priority 17 total filings
· daily

USA Insider Trading Pulse — October 07, 2026

The October 7, 2026 insider trading pulse reveals a market dominated by routine equity awards and tax-withholding dispositions, masking a clear divergence in conviction. Vail Resorts issued a massive wave of stock appreciation rights and restricted stock units to its entire executive suite and board, signaling a long-term retention strategy but no immediate cash conviction. The most actionable signal is the aggressive accumulation by IRIDEX Corp's 10% owner, Lin Shih-Yao David, who has been buying consistently at sub-$1 prices, building a stake now exceeding 1.1 million shares. On the bearish side, a cluster of high-value, pre-planned insider sales at Vaxcyte, Applied Optoelectronics, and Intapp suggests insiders are monetizing gains at elevated valuations. The financial sector shows mixed signals, with Provident Financial Holdings seeing only tax-related dispositions, while Capital One's General Counsel executed a notable 10b5-1 sale. Overall, the period is characterized by heavy award activity in the leisure sector, cautious selling in high-growth tech, and a single, highly-convicted buyer in the micro-cap medical device space.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — October 07, 2026

The October 7, 2026, M&A landscape is dominated by two definitive SPAC business combination agreements (First Digital/FDUSD and KQC Quantum) and a major SPAC IPO (Pine Tree Acquisition Corp.), signaling sustained appetite for bringing high-growth, non-traditional assets to public markets via blank-check vehicles. A key period-over-period trend is the divergence in SPAC health: while new capital is flowing into the space via IPOs, existing SPACs like Launch Two and Columbus Acquisition are showing signs of distress, with repeated meeting postponements and opaque post-merger filings, respectively. The most critical development is the $250 million valuation of First Digital, a stablecoin issuer with $87M in FY2025 revenue, which will test regulatory and market appetite for crypto-native public listings. Meanwhile, Richardson Electronics stands out as a rare operating company in the batch, delivering strong 18.9% YoY revenue growth and 112.6% net income surge, contrasting with the speculative nature of the SPAC filings. A portfolio-level pattern is the concentration of risk in SPACs facing tight deadlines (Charlton Aria must close by Oct 25, 2026) and shareholder redemption pressures, creating binary outcomes for investors. The absence of insider trading activity in the SPAC filings, except for the Sponsor's nominal $0.003/share founder share purchase in Southport II, suggests limited management conviction beyond the deal structure itself.

8 high priority 8 total filings
· monthly

US Pre-Market SEC Filings Roundup — October 07, 2026

Overnight filings reveal a mixed picture for US markets, headlined by a major SPAC deal in digital assets and a critical delisting. First Digital's $250M business combination with CSLM Digital Asset Acquisition Corp brings stablecoin exposure to Nasdaq, while NUSATRIP's imminent delisting serves as a stark warning on micro-cap risk. The most significant period-over-period trend comes from Costco, which reported a robust 10% YoY revenue growth to $297B, though gross margins saw slight compression. Conversely, Odyssey Marine Exploration's financials show a severe deterioration, with revenue halving and losses widening. Insider activity was largely neutral, dominated by routine stock awards and tax-withholding sales at MGM Resorts and Kenvue. A notable capital allocation move was the $61.8M equity investment in Gogoro, signaling confidence in the EV space. The most actionable intelligence centers on the First Digital SPAC, Costco's steady growth, and the risk flags around Odyssey Marine and NUSATRIP.

28 high priority 22 medium 50 total filings
· daily

Biotech Small-Cap Approvals — October 06, 2026

The October 6, 2026 period saw 4 FDA approvals, all classified as 'Other' (FALLBACK type), with zero NMEs, biosimilars, or label expansions. The dominant theme is a single label expansion for EVER VALINJECT (sponsor: Unknown), which generated the only bullish signal, albeit with no disclosed commercial details. The remaining three approvals are biosimilar entries for LEVOCARNITINE (GLAND), PHYTONADIONE (LUPIN), and LOPERAMIDE HYDROCHLORIDE (TARO), all rated neutral due to the lack of disclosed peak sales, exclusivity, or pricing data. The highest-conviction signal is the EVER VALINJECT label expansion, but its investment implication is opaque without indication size or market position data. Key risk is the absence of NME approvals, signaling a low-innovation period for small-cap biotech, and the lack of disclosed commercial details across all approvals limits actionable analysis.

4 total filings
· daily

New Drug Approvals (Original) — October 06, 2026

During the October 6, 2026 period, the FDA approved 4 non-NME, non-biosimilar, non-label-expansion drugs (classified as 'Other'), with a mixed signal profile of 1 bullish and 3 neutral. The period lacked any high-value NME or biosimilar approvals, resulting in minimal therapeutic area clustering or pipeline momentum signals. The only bullish signal came from EVER VALINJECT's label expansion for an undisclosed indication, but the lack of commercial data (peak sales, pricing, market position) limits conviction. The remaining approvals—LEVOCARNITINE (GLAND), PHYTONADIONE (LUPIN), and LOPERAMIDE HYDROCHLORIDE (TARO)—are neutral biosimilar entries in mature markets with no disclosed sales estimates, offering limited investment differentiation. Key watch items include the absence of NMEs, which signals a quiet approval cadence, and the need for further disclosure on EVER VALINJECT's commercial potential.

4 total filings
· daily

S&P 500 Technology Sector SEC Filings — October 06, 2026

The 10 filings from the S&P 500 Technology sector reveal a bifurcated insider sentiment landscape. Accenture plc shows a pattern of routine, low-materiality equity awards to its entire C-suite, signaling stable management retention and alignment at a set price of $196.76. In stark contrast, both Synopsys Inc and CrowdStrike Holdings report high-value insider stock sales by key executives, including a Deputy CFO and the CEO, respectively. The Synopsys sale ($4.59M) by the Deputy CFO & CAO is particularly bearish, representing a significant liquidation of holdings. CrowdStrike’s CEO sales ($1.38M) are executed under a Rule 10b5-1 plan, which provides a layer of insulation from direct sentiment interpretation but still represents a notable reduction in personal exposure. No period-over-period comparisons, forward-looking guidance, capital allocation changes, or M&A activity were present in this batch, limiting the analysis to insider transaction patterns. The dominant theme is a divergence in management conviction: strong, consistent retention at Accenture versus significant profit-taking and de-risking by senior insiders at Synopsys and CrowdStrike.

10 high priority 10 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — October 06, 2026

This digest of 50 SEC filings reveals a market dominated by passive institutional stake adjustments and a few high-conviction activist and control events. The most significant development is the resolution of a proxy contest at Evogene Ltd., where an activist group secured four of seven board seats, signaling a major governance shift. Concurrently, Whitebox Advisors secured a board nomination right at KLX Energy Services after a $19M backstop exchange, while a new controlling shareholder took an 81.48% stake in AGM Group Holdings. On the institutional side, Wellington Management increased its stakes in Redwood Trust (to 17.0%) and Latham Group (to 10.2%), while Capital World Investors disclosed new or increased passive positions in Skyworks Solutions (10.1%), New Fortress Energy (12.2%), and Aura Minerals (10.2%). A notable pattern is the significant passive accumulation in SPACs by Wolverine Asset Management, which disclosed stakes in 10 different blank-check companies, suggesting a strategy of diversified arbitrage. The only clear exit signal came from Starboard Value, which liquidated its entire Qorvo stake following the Skyworks merger. Overall, the period shows a mix of passive rebalancing, targeted activist engagement, and a few transformative control transactions.

11 high priority 39 medium 50 total filings